Todays Report: The Zacks Investment Research Upgrades Imperva Inc. (IMPV) to “Hold”

The Zacks Investment Research Upgrades Imperva Inc. (IMPV) to “Hold”

Imperva Inc. (NYSE:IMPV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Imperva Inc. is engaged in the development of protection software and services for business applications and databases. The Company delivers innovative technology to give full audit accountability and separation of duties to meet regulatory compliance. It offers SecureSphere Data Security Suite to protect sensitive data from hackers and malicious insiders along with providing a fast and cost-effective route to regulatory compliance and establishes a repeatable process for data risk management. The Company’s SecureSphere offers database security solutions to secure sensitive data stored in databases, File Security solutions to protect sensitive files on file servers, storage devices, content repositories, and meet regulatory compliance mandates and Web Application Security solutions to protect web applications from cyber attacks. Imperva Inc. is headquartered in Redwood Shores, California. “

Other research analysts also recently issued research reports about the stock. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. Nomura reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. BTIG Research reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Imperva in a research report on Tuesday, June 21st. Needham & Company LLC reiterated a “hold” rating on shares of Imperva in a research note on Tuesday, June 21st. Finally, Morgan Stanley reiterated a “sell” rating on shares of Imperva in a research note on Thursday, June 30th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $52.33.

Imperva (NYSE:IMPV) opened at 50.50 on Tuesday. The company’s market cap is $1.65 billion. Imperva has a 12 month low of $31.11 and a 12 month high of $77.99. The company’s 50-day moving average is $48.18 and its 200-day moving average is $44.79.

Imperva (NYSE:IMPV) last posted its earnings results on Thursday, August 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.19. The business had revenue of $57.87 million for the quarter, compared to analysts’ expectations of $66.06 million. Imperva had a negative net margin of 23.75% and a negative return on equity of 25.68%. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the business posted ($0.08) EPS. On average, equities research analysts expect that Imperva will post ($0.80) EPS for the current fiscal year.

In related news, insider Amichai Shulman sold 3,085 shares of the company’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $46.28, for a total value of $142,773.80. Following the completion of the sale, the insider now owns 93,380 shares of the company’s stock, valued at $4,321,626.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mark E. Kraynak sold 2,967 shares of the company’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $46.15, for a total transaction of $136,927.05. Following the completion of the sale, the senior vice president now directly owns 2,968 shares of the company’s stock, valued at approximately $136,973.20. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in IMPV. Vanguard Group Inc. raised its stake in shares of Imperva by 8.7% in the second quarter. Vanguard Group Inc. now owns 2,077,265 shares of the company’s stock worth $89,343,000 after buying an additional 165,851 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Imperva by 3.9% in the second quarter. JPMorgan Chase & Co. now owns 1,536,698 shares of the company’s stock worth $66,092,000 after buying an additional 57,686 shares in the last quarter. Credit Suisse AG raised its stake in shares of Imperva by 865.9% in the second quarter. Credit Suisse AG now owns 1,431,447 shares of the company’s stock worth $61,568,000 after buying an additional 1,283,243 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of Imperva by 3.1% in the second quarter. Eagle Asset Management Inc. now owns 1,338,055 shares of the company’s stock worth $57,549,000 after buying an additional 40,709 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its stake in shares of Imperva by 50.6% in the second quarter. Pictet Asset Management Ltd. now owns 804,552 shares of the company’s stock worth $30,718,000 after buying an additional 270,312 shares in the last quarter. 93.26% of the stock is owned by hedge funds and other institutional investors.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

Related posts

Leave a Comment